Tetraphase Pharmaceuticals Ireland Limited was set up on Tuesday the 24th of October 2017. Their current partial address is Dublin 2, and the company status is Dissolved with the company closing on Monday the 30th of May 2022. The company's current directors have been the director of 149 other Irish companies between them; 89 of which are now closed. Tetraphase Pharmaceuticals Ireland Limited has 1 shareholder. This Irish company shares its Eircode with at least 732 other companies.
| Company Name: | Tetraphase Pharmaceuticals Ireland Limited | |
| Company Status: | DISSOLVED | |
| RiskWatch | CEASED TRADING NOTIFICATION | |
| RiskWatch | CEASED TRADING NOTIFICATION | |
| Company Address: | 10 Earlsfort Terrace, Dublin 2 | |
| Key Executive: | Mr Hayes | |
| Company Size: | Log-In To View | |
| Established: | 24/10/2017 (5 years in business). | |
Mr Hayes is a Company Director of Tetraphase Pharmaceuticals Ireland Limited since 2017 and a listed Director of 82 other companies.
Generate a B2B Marketing List with ease and grow your business. Identify key decision makers and pre-qualified new prospects for your sales and business development teams.
Similar Companies - Create a marketing list of similar companies
The latest documents filed with the Companies Registration Office for Tetraphase Pharmaceuticals Ireland Limited (which can include the Account Details) are listed below.
| CRO Document | Effective Date | Received By CRO | View Now | |
|---|---|---|---|---|
| G1H15 SR TO APPLY FOR VOLUNTARY STRIKE OFF | 21/12/2021 | 11/02/2022 | Join Up | |
| Form H15: Application for Voluntary strike-off | 11/02/2022 | 11/02/2022 | Join Up | |
| Form B1C - Annual Return General | 30/09/2021 | 14/01/2022 | Join Up | |
| FINANCIAL STATEMENT | 30/09/2021 | 14/01/2022 | Join Up | |
| Form B1C - Annual Return General | 30/09/2020 | 13/01/2022 | Join Up | |
| THIS COMPANY HAS 10 OTHER DOCS » | ||||
View CRO company documents and company reports any Irish company or business with ease.
View the Latest Credit Report and Credit Limit on Tetraphase Pharmaceuticals Ireland Limited.
| Company Status: | Dissolved | |
| RiskWatch | CEASED TRADING NOTIFICATION | |
| RiskWatch | CEASED TRADING NOTIFICATION | |
| Latest Credit Movement: |  | |
| Date of Last Movement: | 05/08/2025 | |
| Latest Accounts Filed: | 14/01/2022 | |
| Report Based on Accounts: | 31/12/2020 | |
| Next Set of Accounts Due: | 30/09/2022 | |
| Overdue: | Yes | |
| Credit Score: | Join-Up to View | |
To View the latest Credit Rating or Credit Limit on Tetraphase Pharmaceuticals Ireland Limited simply click 'Log-In' or 'Join-Up' below.
Vision-net Credit Scores save your business the time and cost of chasing slow payers. Evaluate risk at client application stage or run continuous credit checks on your full customer base.
Satisfy due diligence requirements on Tetraphase Pharmaceuticals Ireland Limited in one single 'time-saving' search. Run full background checks for Fitness and Probity on the directors of Tetraphase Pharmaceuticals Ireland Limited and Anti-Money Laundering checks (AML checks) on Tetraphase Pharmaceuticals Ireland Limited
| Company Type: | LTD - Private Company Limited By Shares |
| Number of Shareholders: | 1 |
Log-in now to run Due Diligence checks and Compliance checks on Tetraphase Pharmaceuticals Ireland Limited or click Join-up to get started.
Background check Companies, Sole Traders or Individuals and minimise your spend with more efficient Anti-Money Laundering checks and reports.
More people choose Vision-net over any other search service... ask us why?
13/10/2025
The continued emergence of new firms across multiple sectors reflects resilient confidence in the Irish economy.
06/10/2025
Our latest CRIFVision-net data highlights a mixed but promising picture of the Irish economy, with entrepreneurial activity continuing to climb.
22/09/2025
In sectors where trust, transparency, and regulatory adherence are paramount, compliance is not optional - it is foundational.
25/08/2025
At CRIFVision-net, we help you make smarter, faster decisions with trusted data...
